← All trials
NCT02066285
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2014
- Primary completion
- Dec 1, 2016
- Completion date
- Jun 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Grupo Espanol de Investigacion en SarcomasLead sponsor
- Centre Leon BerardOverall official - principal investigator
- University of ZaragozaOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- Hospital Son EspasesStudy director
- University of MilanStudy director
- Universidad Autonoma de MadridOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- Hospital Universitario Central de AsturiasOverall official - principal investigator
- University of Las Palmas de Gran CanariaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.